• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

58.46 -0.54 (-0.92%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,830,940
Open 59.10
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 59.00
Today's Range 58.33 - 59.18
52wk Range 47.05 - 61.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
November 16, 2026
From Genentech
Via Business Wire
News headline image
Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy
November 16, 2026
From Genentech
Via Business Wire

Performance

52-Week Range 5.3% below 52-week high
58.46
47.0552W Low 61.7552W High
1 Week 4.6% below 1-week high
58.331W Low 61.271W High

Roche Holding AG Basel American Depositary Shares (RHHBY) traded between $47.05 and $61.75 over the past 52 weeks and last traded at $58.46, 5.3% below its 52-week high. Over the past week it ranged between $58.33 and $61.27.

Past 12 Months
-4.1%
-1.9%
+1.7%
+11.1%
+13.6%
+19.3%
1W -$2.49
1M -$1.16
3M +$0.99
6M +$5.86
YTD +$7.01
1Y +$9.45

RHHBY was +19.3% over the past year, +11.1% over six months, +13.6% year to date, -4.1% in the last week.

12 Months vs Market
RHHBY
+19.3%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months RHHBY returned +19.3% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 1.18× 3-mo avg
Today 1,830,940 3-mo avg 1.5M
1W
1.4M
1M
1.4M
3M
1.5M
6M
1.8M
YTD
2.2M
1Y
2.2M

RHHBY most recently traded 1,830,940 shares against a 3-month average daily volume of 1.5M.

More News

Read More
News headline image
Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026
November 10, 2026
From Genentech
Via Business Wire
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
November 03, 2026
From FN Media
Via GlobeNewswire
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
November 03, 2026
Via FinancialNewsMedia
News headline image
Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
October 25, 2026
From Genentech
Via Business Wire
News headline image
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
October 23, 2026
From Genentech
Via Business Wire
News headline image
If Economists Are Correct About the Future of AI, Here Are 2 Global ETFs to Buy -- and 2 to Avoid ↗
October 22, 2026
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
There's a New Q in Town: Invesco's ETF Targets International Innovators ↗
October 22, 2026
Via MarketBeat
Topics ETFs
News headline image
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
October 21, 2026
From Genentech
Via Business Wire
News headline image
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗
October 21, 2026
Via The Motley Fool
News headline image
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
October 19, 2026
From Genentech
Via Business Wire
News headline image
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
October 16, 2026
From Genentech
Via Business Wire
News headline image
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
October 10, 2026
From Genentech
Via Business Wire
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
October 10, 2026
Via The Motley Fool
News headline image
FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
October 09, 2026
From Genentech
Via Business Wire
News headline image
Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
October 01, 2026
From Genentech
Via Business Wire
News headline image
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
October 01, 2026
From Genentech
Via Business Wire
News headline image
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
October 01, 2026
From Genentech
Via Business Wire
News headline image
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗
September 30, 2026
Via The Motley Fool
News headline image
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
September 30, 2026
From Genentech
Via Business Wire
News headline image
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
September 28, 2026
From Genentech
Via Business Wire
News headline image
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
September 23, 2026
From Genentech
Via Business Wire
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
September 22, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
September 22, 2026
From Genentech
Via Business Wire

Frequently Asked Questions

Is Roche Holding AG Basel American Depositary Shares publicly traded?
Yes, Roche Holding AG Basel American Depositary Shares is publicly traded.
What exchange does Roche Holding AG Basel American Depositary Shares trade on?
Roche Holding AG Basel American Depositary Shares trades on the OTC Traded
What is the ticker symbol for Roche Holding AG Basel American Depositary Shares?
The ticker symbol for Roche Holding AG Basel American Depositary Shares is RHHBY on the OTC Traded
What is the current price of Roche Holding AG Basel American Depositary Shares?
The current price of Roche Holding AG Basel American Depositary Shares is 58.46
When was Roche Holding AG Basel American Depositary Shares last traded?
The last trade of Roche Holding AG Basel American Depositary Shares was at 11/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap